Cita APA

Hara, I., Yamashita, S., Nishizawa, S., Kikkawa, K., Shimokawa, T., & Kohjimoto, Y. (2018). Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial. JMIR Res Protoc.

Citación estilo Chicago

Hara, Isao, Shimpei Yamashita, Satoshi Nishizawa, Kazuro Kikkawa, Toshio Shimokawa, y Yasuo Kohjimoto. "Enzalutamide Versus Abiraterone As a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial." JMIR Res Protoc 2018.

Cita MLA

Hara, Isao, et al. "Enzalutamide Versus Abiraterone As a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial." JMIR Res Protoc 2018.